Regional brain activation during verbal declarative memory in metastatic breast cancer

Clinical Cancer Research

Volumn 15, Issue 21, 2009, Pages 6665-6673

  Kesler, Shelli R ^a   Bennett, F Chris ^a   Mahaffey, Misty L ^a   Spiegel, David ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; HYDROCORTISONE; METHOTREXATE; PACLITAXEL; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BRAIN REGION; BREAST CANCER; CANCER CHEMOTHERAPY; CIRCADIAN RHYTHM; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DECLARATIVE MEMORY; DISTRESS SYNDROME; ELECTROENCEPHALOGRAM; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GROUPS BY AGE; HUMAN; LIMBIC SYSTEM; MEMORY DISORDER; METASTASIS; MULTIPLE CYCLE TREATMENT; PATIENT EDUCATION; PREFRONTAL CORTEX; PRIORITY JOURNAL; RECALL; RISK ASSESSMENT; SALIVA LEVEL; VERBAL MEMORY;

BRAIN; BREAST NEOPLASMS; FEMALE; HUMANS; HYDROCORTISONE; MAGNETIC RESONANCE IMAGING; MEMORY; MEMORY DISORDERS; MIDDLE AGED; NEOPLASM METASTASIS; NEUROPSYCHOLOGICAL TESTS; VERBAL BEHAVIOR;

EID: 70350702789     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1227     Document Type: Article

References (47)

1. Burstein HJ. Cognitive side-effects of adjuvant treatments. Breast 2007;16 Suppl 2:S166-8.
2. Stewart A, Collins B, Mackenzie J, Tomiak E, Verma S, Bielajew C. The cognitive effects of adjuvant chemotherapy in early stage breast cancer: a prospective study. Psychooncology 2007;17: 122-130
3. Taillibert S, Voillery D, Bernard-Marty C. Chemobrain: Is systemic chemotherapy neurotoxic? Curr Opin Oncol 2007;19:623-627
4. O'Shaughnessy J. Chemotherapy-related cognitive dysfunction in breast cancer. Semin Oncol Nurs 2003;19:17-24. (Pubitemid 40434443)
5. Silverman DH, Dy CJ, Castellon SA, et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat 2007;103:303-311
6. Inagaki M, Yoshikawa E, Matsuoka Y, et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 2006. (Pubitemid 46120202)
7. Abraham J, Haut M, Moran M, Filburn S, Lemiuex S, Kuwabara H. Adjuvant chemotherapy for breast cancer: effects on cerebral white matter seen in diffusion tensor imaging. Clin Breast Cancer 2008;8:88-91. (Pubitemid 351346234)
8. Ferguson RJ, McDonald BC, Saykin AJ, Ahles TA. Brain structure and function differences in monozygotic twins: possible effects of breast cancer chemotherapy. J Clin Oncol 2007;25: 3866-3870
9. D'Esposito M. Functional neuroimaging of cognition. Semin Neurol 2000;20:487-498
10. Kotsoni E, Byrd D, Casey BJ. Special considerations for functional magnetic resonance imaging of pediatric populations. J Magn Reson Imaging 2006;23:877-886 (Pubitemid 43833157)
11. Poldrack RA, ParÇ-Blagoev EJ, Grant PE. Pediatric functional magnetic resonance imaging: progress and challenges. Top Magn Reson Imaging 2002;13:61-70. (Pubitemid 34194115)
12. Wilke M, Holland SK, Myseros JS, Schmithorst VJ, Ball WS. Functional magnetic resonance imaging in pediatrics. Neuropediatrics 2003;34: 225-233 (Pubitemid 37411728)
13. Strangman G, O'Neil-Pirozzi TM, Burke D, et al. Functional neuroimaging and cognitive rehabilitation for people with traumatic brain injury. Am J Phys Med Rehabil 2005;84:62-75. (Pubitemid 40053294)
14. Wefel JS, Lenzi R, Theriault R, Buzdar AU, Cruickshank S, Meyers CA. 'Chemobrain' in breast carcinoma?: a prologue. Cancer 2004; 101:466-475
15. Abercrombie HC, Giese-Davis J, Sephton S, Epel ES, Turner-Cobb JM, Spiegel D. Flattened cortisol rhythms in metastatic breast cancer patients. Psychoneuroendocrinology 2004;29: 1082-1092 (Pubitemid 38833536)
16. Spiegel D, Giese-Davis J, Taylor CB, Kraemer H. Stress sensitivity in metastatic breast cancer: analysis of hypothalamic-pituitary-adrenal axis function. Psychoneuroendocrinology 2006; 31:1231-1244 (Pubitemid 44792371)
17. Kreukels BP, Schagen SB, Ridderinkhof KR, Boogerd W, Hamburger HL, van Dam FS. Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy. Breast Cancer Res Treat 2005;94:53-61. (Pubitemid 41416942)
18. Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 2004;26:955-969 (Pubitemid 39577316)
19. Palmer JL, Trotter T, Joy AA, Carlson LE. Cognitive effects of Tamoxifen in pre-menopausal women with breast cancer compared to healthy controls. J Cancer Surviv 2008;2:275-282
20. Schilder CM, Eggens PC, Seynaeve C, et al. Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study. Acta Oncol 2009; 48:76-85.
21. Dietrich J, Han R, Yang Y, Mayer-Prîschel M, Noble M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 2006;5:22. (Pubitemid 46251347)
22. Seigers R, Schagen SB, Beerling W, et al. Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat. Behav Brain Res 2008; 186:168-175 (Pubitemid 350122748)
23. Winocur G, Vardy J, Binns MA, Kerr L, Tannock I. The effects of the anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice. Pharmacol Biochem Behav 2006;85:66-75. (Pubitemid 44802737)
24. Irwin M, Daniels M, Risch SC, Bloom E, Weiner H. Plasma cortisol and natural killer cell activity during bereavement. Biol Psychiatry 1988;24: 173-178 (Pubitemid 18137513)
25. Kirschbaum C, Hellhammer DH. Salivary cortisol in psychobiological research: an overview. Neuropsychobiology 1989;22:150-169 (Pubitemid 20291714)
26. Kirschbaum C, Hellhammer DH. Salivary cortisol in psychoneuroendocrine research: recent developments and applications. Psychoneuroendocrinology 1994;19:313-333 (Pubitemid 24150545)
27. Weinberger DA, Schwartz GE. Distress and restraint as superordinate dimensions of self-reported adjustment: a typological perspective. J Pers 1990;58:381-417.
28. Gallagher D, Nies G, Thompson LW. Reliability of the Beck Depression Inventory with older adults. J Consult Clin Psychol 1982;50:152-153
29. Glover GH, Lai S. Self-navigated spiral fMRI: interleaved versus single-shot. Magn Reson Med 1998;39:361-368 (Pubitemid 28128378)
30. Greicius MD, Krasnow B, Boyett-Anderson JM, et al. Regional analysis of hippocampal activation during memory encoding and retrieval: fMRI study. Hippocampus 2003;13:164-174 (Pubitemid 36305404)
31. Mazaika P, Whitfield-Gabrielli S, Reiss AL. Aritfact repair for fMRI data from high motion clinical subjects. In: Human Brain Mapping; 2007; 2007.
32. Friston KJ. Commentary and opinion: II. Statistical parametric mapping: ontology and current issues. J Cereb Blood Flow Metab 1995;15:361-370
33. Holmes AP, Friston KJ. Generalisability, random effects, and population inference. Neuroimage 1998;7:S754. (Pubitemid 128673256)
34. Menon V, Boyett-Anderson JM, Schatzberg AF, Reiss AL. Relating semantic and episodic memory systems. Brain Res Cogn Brain Res 2002;13:261-265 (Pubitemid 34212052)
35. Eichenbaum H. A cortical-hippocampal system for declarative memory. Nat Rev Neurosci 2000; 1:41-50.
36. Collins B, Mackenzie J, Stewart A, Bielajew C, Verma S. Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. Psychooncology 2009;18:134-143
37. Hermelink K, Untch M, Lux MP, et al. Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. Cancer 2007;109: 1905-1913 (Pubitemid 46668557)
38. Weis J, Poppelreuter M, Bartsch HH. Cognitive deficits as long-term side-effects of adjuvant therapy in breast cancer patients: 'subjective' complaints and 'objective' neuropsychological test results. Psychooncology 2008.
39. O'Hara R, Yesavage JA, Kraemer HC, et al. The APOE ε4 allele is associated with decline on delayed recall performance in community-dwelling older adults. J Am Geriatr Soc 1998; 46:1493-1498 (Pubitemid 28551194)
40. Ahles TA, Saykin AJ, Noll WW, et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology 2003;12:612-619
41. Lesnik PG, Ciesielski KT, Hart BL, Benzel EC, Sanders JA. Evidence for cerebellar-frontal subsystem changes in children treated with intrathecal chemotherapy for leukemia: enhanced data analysis using an effect size model. Arch Neurol 1998;55:1561-1568 (Pubitemid 28566626)
42. Lepage M, Ghaffar O, Nyberg L, Tulving E. Prefrontal cortex and episodic memory retrieval mode. Proc Natl Acad Sci U S A 2000;97:506-511 (Pubitemid 30055861)
43. Zilles K, Dabringhaus A, Geyer S, et al. Structural asymmetries in the human forebrain and the forebrain of non-human primates and rats. Neurosci Biobehav Rev 1996;20:593-605. (Pubitemid 27043861)
44. Klingberg T, Vaidya CJ, Gabrieli JD, Moseley ME, Hedehus M. Myelination and organization of the frontal white matter in children: a diffusion tensor MRI study. Neuroreport 1999;10: 2817-2821 (Pubitemid 30004111)
45. Baslow MH. Functions of N-acetyl-L-aspartate and N-acetyl-L- aspartylglutamate in the vertebrate brain: role in glial cell-specific signaling. J Neurochem 2000;75:453-459
46. Fisher MJ, Khademian ZP, Simon EM, Zimmerman RA, Bilaniuk LT. Diffusion-weighted MR imaging of early methotrexate-related neurotoxicity in children. AJNR Am J Neuroradiol 2005;26:1686-1689
47. Linnebank M, Moskau S, Jurgens A, et al. Association of genetic variants of methionine metabolism with methotrexate-induced CNS white matter changes in patients with primary CNS lymphoma. Neuro Oncol 2009;11:2-8.